Posted by Michael Wonder on 09 Oct 2023
Ravulizumab for the treatment of adults with generalised myasthenia gravis
4 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using ravulizumab in the NHS in England.
Ravulizumab is not recommended as an add-on to standard treatment for adults with generalised myasthenia gravis who test positive for anti-acetylcholine receptor antibodies.
